|
|
Article: Aronex Pharmaceuticals Reports Data on NYOTRAN(R) Antifungal Agent at European Congress of Clinical Microbiology and Infectious Disease.
- Article from:
- PR Newswire
- Article date:
- March 25, 1999
CopyrightCOPYRIGHT 1999 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NYOTRAN(R) Exhibits Differentiating Antifungal Activity
THE WOODLANDS, Texas, March 25 /PRNewswire/ -- Aronex Pharmaceuticals, Inc. (Nasdaq: ARNX) today announced the presentation of data on NYOTRAN(R) demonstrating broad antifungal activity against filamentous fungi, the most difficult type to treat. This in vitro study, conducted by clinical researchers in Spain, tested NYOTRAN in 100 fungal samples and compared NYOTRAN's activity to currently commercialized antifungal agents. Results were presented at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) conference held in Berlin, Germany. NYOTRAN is Aronex Pharmaceutical's ...